Effect of gastric bypass surgery on azithromycin oral bioavailability

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 9, 2012, Pages 2203-2206

  Padwal, Raj S ^a,b   Ben Eltriki, Mohamed ^a   Wang, Xiaoming ^a   Langkaas, Lee Ann ^b   Sharma, Arya M ^a   Birch, Dan W ^a   Karmali, Shahzeer ^a   Brocks, Dion R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bariatric surgery; Drug absorption; Obesity

Indexed keywords

AZITHROMYCIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAXIMUM PLASMA CONCENTRATION; SINGLE DRUG DOSE; STOMACH BYPASS; SURGICAL PATIENT; TABLET FORMULATION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; BIOLOGICAL AVAILABILITY; FEMALE; GASTRIC BYPASS; HUMANS; MIDDLE AGED; PLASMA; TIME FACTORS; YOUNG ADULT;

EID: 84865380118     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks177     Document Type: Article

References (10)

1. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 370-4.
2. Mandell LA, Marrie TJ, Grossman RF et al. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J 2000; 7: 371-82.
3. Marrie TJ, Huang JQ. Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study. Can Respir J 2005; 12: 139-42.
4. Houck PM, Bratzler DW, Nsa Wet al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with communityacquired pneumonia. Arch Intern Med 2004; 164: 637-44.
5. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2008. Obes Surg 2009; 19: 1605-11.
6. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010; 11: 41-50.
7. Dunn CJ, Barradell LB. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996; 51: 483-505.
8. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 Suppl A: 73-82.
9. Amsden GW. Pneumococcal macrolide resistance-myth or reality? J Antimicrob Chemother 1999; 44: 1-6.
10. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817-24.